stockrow
Friday 6 November 2026
Export OPK’s income statement to Excel — free account
OPKO Health, Inc.
OPK Healthcare Diagnostics & Research
- Revenue
- −56.9%
- EPS
- −333.3%
- Free cash flow
- −3.40%
- Total debt
- +40.7%
Quarter to September 2026, against a year earlier
1.74
0.01
−0.57%
Follow OPK
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.56 | 1.49 | 1.93 | 2.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(36.51) | (44.80) | (26.04) | (33.09) | |
P/B ratio |
0.75 | 0.72 | 0.96 | 1.08 | |
Price to Tangible BV |
3.54 | 3.83 | 5.03 | 2.98 | |
EV/Sales |
1.51 | 1.49 | 2.01 | 2.56 | |
EV/EBITDA |
0.00 | 0.00 | 28.07 | 0.00 | |
EV/Operating CF |
(5.15) | (5.31) | (9.56) | (10.27) | |
EV/FCF |
(4.58) | (4.71) | (8.21) | (8.86) | |
Quick Ratio |
3.13 | 2.84 | 2.56 | 2.90 | |
Current Ratio |
3.97 | 3.61 | 3.35 | 4.97 | |
Net Debt/EBITDA |
1.73 | (0.06) | 2.99 | (8.48) | |
Debt/Assets |
17.69% | 18.51% | 18.98% | 24.61% | |
Debt/Equity |
0.27 | 0.29 | 0.29 | 0.41 | |
Asset Turnover |
0.29 | 0.29 | 0.31 | 0.26 | |
Operating CF/Net income |
0.83 | 0.35 | 5.17 | 0.68 | |
Capex/Depreciation |
(0.11) | (0.08) | (0.13) | (0.12) | |
Interest Coverage |
(3.39) | (4.66) | (0.61) | (2.34) | |
Research and Development Expense of Revenue |
22.08% | 23.51% | 20.28% | 49.19% | |
Selling, General and Administrative Expense of Revenue |
34.03% | 39.14% | 32.35% | 37.97% | |
Intangible Assets out of Total Assets |
0.52 | 0.53 | 0.52 | 0.38 | |
Share Based Compensation of Revenue |
1.96% | 2.20% | 1.37% | 3.06% | |
Graham Net Nets |
(0.09) | (0.13) | (0.13) | 0.04 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(23.81%) | (23.68%) | (6.00%) | (11.80%) | |
Free Cash Flow Yield |
(21.19%) | (21.26%) | (12.69%) | (12.07%) | |
Revenue per Share |
0.20 | 0.16 | 0.22 | 0.09 | |
Operating CF per Share |
(0.03) | (0.03) | (0.06) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.03) | (0.06) | (0.05) | |
Cash per Share |
0.49 | 0.45 | 0.40 | 0.52 | |
Shareholders Equity per Share |
1.69 | 1.59 | 1.57 | 1.50 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.69 | 1.59 | 1.57 | 1.50 | |
Free Cash Flow |
(28.49) | (21.11) | (46.36) | (39.05) | |
Working Capital |
435.20 | 386.98 | 350.87 | 643.92 | |
Capital Expenditures |
(2.57) | (1.80) | (2.86) | (2.74) | |
Net Current Asset Value |
(82.10) | (116.82) | (145.05) | 42.20 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.02 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
104.14 | 87.89 | 90.63 | 87.40 | |
Average Payables |
44.09 | 51.77 | 53.36 | 49.37 | |
Average Inventory |
61.31 | 64.20 | 64.10 | 57.78 | |
Average Assets |
2,066.08 | 1,992.56 | 1,901.22 | 1,937.88 | |
Average Common Equity |
1,316.70 | 1,258.14 | 1,240.54 | 1,210.83 |
Columns are period end dates · fundamentals updated 4 Nov 2026